M&A Deal Summary

Bausch Health Acquires Eyetech Pharmaceuticals

On March 1, 2012, Bausch Health acquired life science company Eyetech Pharmaceuticals from OSI Pharmaceuticals for 22M USD

Acquisition Highlights
  • This is Bausch Health’s 12th transaction in the Life Science sector.
  • This is Bausch Health’s 24th largest (disclosed) transaction.
  • This is Bausch Health’s 7th transaction in the United States.
  • This is Bausch Health’s 4th transaction in New Jersey.

M&A Deal Summary
Date 2012-03-01
Target Eyetech Pharmaceuticals
Sector Life Science
Buyer(s) Bausch Health
Sellers(s) OSI Pharmaceuticals
Deal Type Divestiture
Deal Value 22M USD

Target

Eyetech Pharmaceuticals

Cedar Knolls, New Jersey, United States
Eyetech Pharmaceuticals was founded to discover and develop new drugs to reduce and prevent serious vision loss caused by eye disease. Eyetech's lead product, EYE001, addresses the two leading causes of blindness in the adult population-age-related macular degeneration (AMD) and diabetic macular edema (DME).

Search 200,197 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Bausch Health

Laval, Quebec, Canada
Category Company
Sector Life Science
Employees20,270
Revenue 8.8B USD (2023)
DESCRIPTION

Bausch Health is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology, and branded generics. Bausch Health is based in Laval, Quebec.

DEAL STATS #
Overall 17 of 35
Sector (Life Science) 12 of 21
Type (Divestiture) 6 of 9
State (New Jersey) 4 of 5
Country (United States) 7 of 22
Year (2012) 2 of 6
Size (of disclosed) 24 of 27
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-02-01 Probiotica Laboratorios

Brazil

Probiotica Laboratorios Ltda. is a provider of sports nutrition and food supplements in Brazil. Probiotica currently markets a full line of over-the-counter sports nutrition products and other food supplements.

Buy R$150M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2012-03-13 Gerot Lannach Holding

Austria

Buy -

Seller(S) 1

SELLER

OSI Pharmaceuticals

Farmingdale, New York, United States
Category Company
Founded 1983
Sector Life Science
DESCRIPTION

OSI Pharmaceuticals Inc. is an oncology drug discovery and translational research company, primarily focused on the discovery of molecular targeted therapies.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (New Jersey) 1 of 1
Country (United States) 1 of 1
Year (2012) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2005-08-22 Eyetech Pharmaceuticals

Cedar Knolls, New Jersey, United States

Eyetech Pharmaceuticals was founded to discover and develop new drugs to reduce and prevent serious vision loss caused by eye disease. Eyetech's lead product, EYE001, addresses the two leading causes of blindness in the adult population-age-related macular degeneration (AMD) and diabetic macular edema (DME).

Buy $935M
Mergr

Product

Company

Legal